Entering text into the input field will update the search result below

TTNP Titan Pharmaceuticals, Inc.
Stock Price & Overview

$0.480.03 (+5.48%)3:55 PM 09/22/23
NASDAQ | $USD | Post-Market: $0.49 +0.01 (+2.28%) 7:10 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Company Profile

Titan Pharmaceuticals, Inc. logo
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
  • 400 Oyster Point Boulevard
  • Suite 505
  • South San Francisco, CA, 94080
  • United States
Phone Number
650 244 4990
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.